Nissen, S. E., Tuzcu, E. M., Schoenhagen, P. et al. For the reversal of atherosclerosis with aggressive lipid lowering (REVERSAL) investiga¬tors statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. N. Engl. J. Med., 352:29–38, 2005.
Pietinen, P., and Huttunen, J. K. The dietary determinants of plasma high density lipoprotein cholesterol. Am. Heart J., 113:620–25, 1987.
Ridker, P. M., Cannon, C. P., Morrow, D. et al. For the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis in Myocardial Infarction 22 (PROVE IT–TIMI 22) Investigator: C-reactive protein levels and outcomes after statin therapy. N. Eng. J. Med., 352:20–28, 2005.
Scandinavian simvastatin survival Study group: Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival study (4S). Lancet, 344:1383, 1994.
Shepherd, J., Cobbe, S. M., Ford, I. et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N. Engl. J. Med., 333:1301, 1995.
Toth, P. P. et al. The ‘‘good cholesterol’’: High-density lipoprotein. Circulation, 111:e89-e91, 2005.
Yonemura, A., Momiyama, Y., Zahi, A., Fayad, Z. A. et al. Effect of lipid-lowering therapy with atorvastatin on atherosclerotic aortic plaques detected by noninvasive magnetic resonance imaging. J. Am. Coll. Cardiol., 45:733-74, 2005.

Страницы: 1 | 2 | 3